Early decreases in blood eosinophil levels with reslizumab

Slides:



Advertisements
Similar presentations
Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.
Advertisements

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria  Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,
D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS 
Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.
Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M
Alalia Berry, MD, William W. Busse, MD 
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.
Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 
The Editors' Choice Journal of Allergy and Clinical Immunology
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Practice Notes from the AAAI
Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial  Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.
The Editors' Choice Journal of Allergy and Clinical Immunology
A randomized multicenter study evaluating Xolair persistence of response after long- term therapy  Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,
Kevin Murphy, MD, Joshua Jacobs, MD, Leif Bjermer, MD, John M
Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison  William Busse, MD, Geoffrey Chupp,
The National Biome Initiative: An allergy perspective
Practice Notes from the AAAAI
Jon Genuneit, MD, MSc  Journal of Allergy and Clinical Immunology 
A methodological assessment of diurnal variability of peak flow as a basis for comparing different inhaled steroid formulations  John H. Toogood, MD,
A survivor: The eosinophil as a regulator in asthma
Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation  Leif Bjermer, MD  Journal of Allergy.
News & Notes Journal of Allergy and Clinical Immunology
Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria  Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,
Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management  Scott H. Sicherer, MD, Hugh A. Sampson, MD  Journal.
News Beyond Our Pages Journal of Allergy and Clinical Immunology
Nicola A. Hanania, MB BS, MS, Bradley E. Chipps, MD, Noelle M
News Beyond Our Pages Journal of Allergy and Clinical Immunology
Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS 
News Beyond Our Pages Journal of Allergy and Clinical Immunology
The Editors' Choice Journal of Allergy and Clinical Immunology
Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma  William.
What is an “eosinophilic phenotype” of asthma?
Autophagy: Nobel Prize 2016 and allergy and asthma research
News & Notes Journal of Allergy and Clinical Immunology
News Beyond Our Pages Journal of Allergy and Clinical Immunology
News Beyond Our Pages Journal of Allergy and Clinical Immunology
News Beyond Our Pages Journal of Allergy and Clinical Immunology
Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment
Advances in the approach to the patient with food allergy
News Beyond Our Pages Journal of Allergy and Clinical Immunology
News Beyond Our Pages Journal of Allergy and Clinical Immunology
News Beyond Our Pages Journal of Allergy and Clinical Immunology
The Editors' Choice Journal of Allergy and Clinical Immunology
Practice Notes from the AAAI
News Beyond Our Pages Journal of Allergy and Clinical Immunology
Measles and immunomodulation
Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M
Footnotes1 Journal of Allergy and Clinical Immunology
The Editors' Choice Journal of Allergy and Clinical Immunology
Macrolide antibiotics and asthma treatment
Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge  Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.
Asthma: The past, future, environment, and costs
Albert Y. Wu, MD, Sanjiv Sur, MD, J. Andrew Grant, MD 
Environmental factors and eosinophilic esophagitis
News & Notes Journal of Allergy and Clinical Immunology
News Beyond Our Pages Journal of Allergy and Clinical Immunology
Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma  Oliver Noga, MD, Gerald Hanf, MD,
Systemic responses after bronchial aspirin challenge in sensitive patients with asthma  Joanna S. Makowska, MD, PhD, Janina Grzegorczyk, PhD, Barbara Bienkiewicz,
News Beyond Our Pages Journal of Allergy and Clinical Immunology
Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease  Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,
Natural history of cow’s milk allergy
In lasting tribute: Burton Zweiman, June 7, 1931–December 24, 2013
Primary prevention of asthma and allergy
News Beyond Our Pages Journal of Allergy and Clinical Immunology
Advances in mechanisms of allergic disease in 2016
Presentation transcript:

Early decreases in blood eosinophil levels with reslizumab Pascal Chanez, MD, Mirna McDonald, MS, Margaret Garin, MD, Kevin Murphy, MD  Journal of Allergy and Clinical Immunology  Volume 143, Issue 4, Pages 1653-1655 (April 2019) DOI: 10.1016/j.jaci.2018.12.997 Copyright © 2019 Terms and Conditions

Fig 1 Mean eosinophil counts over 52 weeks of treatment with reslizumab or placebo in patients with early eosinophil data (study 1 only) and all patients in studies 1 and 2. EOS, Eosinophil count data. P values shown for treatment difference (reslizumab vs placebo) at specified time point. All P values derived from Student t test. Treatment differences at baseline were not significant in study 1 or studies 1 and 2. *P < .001. Journal of Allergy and Clinical Immunology 2019 143, 1653-1655DOI: (10.1016/j.jaci.2018.12.997) Copyright © 2019 Terms and Conditions